A Multicenter, Randomized Trial for Stage IIIB or IV NSCLC Comparing Weekly Taxol(Paclitaxel) and Carboplatin(Paraplatin) Regimen Versus Standard Taxol and Carboplatin Administered Every Three Weeks, Followed by Weekly Taxol.

Bristol-Myers Squibb56 个研究点分布在 1 个国家目标入组 444 人开始时间: 2000年6月1日最近更新: 2016年9月19日

适应症

试验速览

Taxol and carboplatin are commonly used drugs for the treatment of stage IIIB or IV non small cell lung carcinoma.

This study compares treatment with Taxol/carboplatin given every 3 weeks to a schedule where it is given weekly.

The purpose of the study is to determine the most effective and safe schedule for giving these drugs in non small cell lung carcinoma.

•Confirmation of non-small cell bronchogenic carcinoma (epidermoid, squamous, adeno, large cell anaplastic carcinoma, but no small cell or carcinoid) must be histologically or cytologically confirmed.
•No prior antineoplastic chemotherapy, hormonal therapy or therapy with biological response modifiers
•No previous irradiation to the only area of measurable disease.

•Past or current history of neoplasm other than the entry diagnosis. Exceptions are curatively treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix or other cancers treated by surgery or radiation with a disease free survival longer than 5 years.
•Patients who have undergone surgery less than 3 weeks prior to enrollment.
•History of serious cardiac disease not adequately controlled.
•Patients with serious active infections or other serious underlying medical condition.
•Uncontrolled diabetes mellitis.

发起方

Bristol-Myers Squibb

申办方类型

Industry

Loading locations...